Is lamotrigine (Lamictal) safe for use in patients with Parkinson's disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lamotrigine Safety in Parkinson's Disease

Lamotrigine (Lamictal) is not recommended for use in patients with Parkinson's disease, as clinical trials have failed to demonstrate antiparkinsonian efficacy and there are concerning associations between antiepileptic drugs and incident Parkinson's disease.

Evidence Against Use in Parkinson's Disease

The clinical evidence consistently shows lamotrigine lacks therapeutic benefit in PD:

  • Two double-blind, placebo-controlled trials specifically tested lamotrigine in PD patients and found no significant improvement in motor symptoms 1, 2. The larger crossover study was particularly telling: 9 of 12 patients discontinued lamotrigine due to worsening dyskinesia (n=2), hallucinations (n=3), and deterioration of parkinsonian symptoms (n=4) 2.

  • Animal models similarly failed to show antiparkinsonian activity, with lamotrigine demonstrating no benefit in reserpinized rats or 6-hydroxydopamine lesioned models when given alone or combined with dopamine agonists 3.

Epidemiological Concerns

Recent large-scale observational studies raise additional safety concerns:

  • A UK Biobank nested case-control study (n=1,433 PD cases, 8,598 controls) found antiepileptic drug prescriptions were associated with 1.80 times higher odds of incident PD (95% CI: 1.35-2.40), with a dose-response relationship showing greater risk with more prescriptions 4.

  • A German primary care database study (n=24,950 matched pairs) confirmed this association, finding any AED prescription was associated with 1.43 times higher odds of subsequent PD diagnosis (95% CI: 1.33-1.53), even after adjusting for epilepsy, restless legs syndrome, and neuropathy 5.

While these studies cannot establish causality and may reflect confounding by indication (epilepsy itself is associated with PD risk), they provide no reassurance about lamotrigine safety in this population.

FDA Labeling Considerations

The FDA label for lamotrigine does not specifically address use in Parkinson's disease 6. However, it notes that lamotrigine clearance may be affected in elderly patients (common PD demographic), with mean half-life of 31.2 hours in patients aged 65-76 years 6.

Clinical Context

The theoretical rationale for lamotrigine in PD—that it inhibits presynaptic glutamate release and might counteract excessive glutamatergic transmission in the basal ganglia—has not translated into clinical benefit 1, 7. The one positive finding was limited to a small pilot study showing investigator-assessed improvement (6/10 vs 2/10, p<0.05) without objective motor improvements 1.

Practical Recommendation

If a patient with Parkinson's disease requires seizure management:

  • Prioritize alternative antiepileptic drugs with established safety profiles in PD
  • Avoid lamotrigine unless other options are contraindicated or have failed
  • If lamotrigine must be used, monitor closely for worsening motor symptoms, hallucinations, and dyskinesia
  • Consider neurology consultation for medication selection in this complex scenario

The convergence of negative efficacy trials, concerning epidemiological associations, and high discontinuation rates due to adverse effects in PD patients makes lamotrigine a poor choice for this population.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.